Deal read Count the upfront. Against roughly $3.5 billion of total potential consideration, J&J committed $785 million on signing, about 22 percent. That sits precisely where an option deal should: far above the six cents on the dollar that licensing averaged across the first half, well below the roughly 75 cents completed M&A settles at. J&J is paying real money, including a substantial equity stake, for the right to decide later. What makes the number striking is what it buys. SAIL-0839 has not entered humans and its target diseases have not been disclosed, so this is $785 million for optionality on preclinical science, which is the opposite of the pattern GSK executed this month when it closed the Nuvalent acquisition and had an approval seven days later. One company bought certainty; this one bought a position in a technology that does not yet exist in patients. The strategic reason is visible in J&J’s own results. Immunology fell 3.7 percent last quarter as STELARA gave up more than half its revenue to biosimilars, and TREMFYA is growing but not fast enough to close the gap. In vivo CAR-T in autoimmune disease is a bet on the franchise after the current one, and the dilution disclosure, $1.28 a share in 2027, is the company saying so in the only language that cannot be softened.